Clinical trials: Active Rheumatoid Arthritis
Rheumatoid Arthritis
Efficacy, Safety and Tolerability of ACZ885 in Patients With Active Rheumatoid Arthritis
The 12-week core study was designed to evaluate risk-benefit of three subcutaneous dose regimens of ACZ885, added on to stable methotrexate (MTX) therapy (greater than or equal to 7.5 mg/week), compared to placebo in patients…
- Trial name
- NCT00424346
- Testing
- Canakinumab
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 274 people
- Sponsor
- Novartis
Rheumatoid Arthritis
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs)
This observational study will evaluate the safety and efficacy of tocilizumab in participants with active moderate to severe RA and an inadequate response to non-biologic DMARDs.
- Trial name
- NCT01617005
- Testing
- Tocilizumab
- Where
- Montenegro
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Active Rheumatoid Arthritis
A Study to Assess the Safety and Efficacy of Different Doses of ELV001 to Treat Active Rheumatoid Arthritis in Patients With an Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)
This is a Phase 2 randomized, double-blind, placebo-controlled study with a total duration of 32 weeks from Screening to End-of-Study (EOS) Visit. Approximately 180 participants are planned to be enrolled.
- Trial name
- NCT07409103
- Testing
- ELV001 25 mg, ELV001 75 mg, ELV001 125 mg
- Where
- 34 sites in United States, Serbia and 1 more
- Volunteers
- 180 people
- Sponsor
- Elevara Medicines Limited
Rheumatoid Arthritis
Safety and Preliminary Efficacy of MOR103 in Patients With Active Rheumatoid Arthritis
GM-CSF is considered to have a key role in the initiation and progression of arthritic inflammation. The purpose of this study is to evaluate the safety, preliminary efficacy, pharmacokinetics, and immunogenicity of multiple…
- Trial name
- NCT01023256
- Testing
- MOR103
- Where
- 5 sites in Bulgaria, Germany and 3 more
- Volunteers
- 96 people
- Sponsor
- MorphoSys AG
Rheumatoid Arthritis
Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis
This is a 12 week open label pilot study to determine the efficacy and safety of a surgically implanted, electrically active vagal nerve stimulation device in patients with active rheumatoid arthritis.
- Trial name
- NCT01552941
- Testing
- Cyberonics VNS System
- Where
- 4 sites in Bosnia and Herzegovina, Croatia and 1 more
- Volunteers
- 18 people
- Sponsor
- SetPoint Medical Corporation
Rheumatoid Arthritis
SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on Anti-TNF Alfa Therapy
This study will compare the efficacy and safety of re-treatment with 2 doses of MabThera (rituximab) in patients with active rheumatoid arthritis (RA) who have previously experienced an inadequate response or intolerance to…
- Trial name
- NCT01126541
- Testing
- rituximab
- Where
- 53 sites in France
- Volunteers
- 224 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis.
This open-label, single-arm, non-randomized study will evaluate the adherence and persistence to tocilizumab therapy in patients with moderate to severe active rheumatoid arthritis, who have an inadequate clinical response to…
- Trial name
- NCT01010503
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- Slovakia
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory disease that primarily affects the joints, causing pain, swelling, stiffness, and loss of function.
- Trial name
- NCT07904754
- Testing
- ABBV-722, Upadacitinib
- Volunteers
- 250 people
- Sponsor
- AbbVie
Seropositive RA
The BCD-089 (aIL6R) in Patients With Active Rheumatoid Arthritis
The study is Phase II randomized, double-blind, placebo-controlled clinical trial to evaluate efficacy and safety, pharmacokinetics and pharmacodynamics of 2 dosing regimens (qw and q2w, s/c) of monoclonal antibody to IL6R…
- Trial name
- AURORA (NCT03455842)
- Testing
- BCD-089, 162 mg, s/c, qw, BCD-089, 162 mg, s/c, q2w
- Where
- 4 sites in Belarus, Russia
- Volunteers
- 105 people
- Sponsor
- Biocad
Rheumatoid Arthritis
A Study of Liquid Certolizumab Pegol as Additional Medication to Methotrexate in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis
A 24 week study in which patients are given study medication and assessed for signs and symptoms of rheumatoid arthritis. X-rays are performed to assess the progress of joint damage during the study.
- Trial name
- NCT00160602
- Testing
- Certolizumab Pegol
- Where
- 70 sites in United States, Bulgaria and 13 more
- Volunteers
- 590 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis
The purpose of this study is to evaluate safety and tolerability of JNJ-67484703 administrations in participants with active rheumatoid arthritis (RA).
- Trial name
- NCT04985812
- Testing
- JNJ-67484703
- Where
- 11 sites in United States, Georgia and 4 more
- Volunteers
- 44 people
- Sponsor
- Janssen Research & Development, LLC
Inflammation, Rheumatoid Arthritis
Efficacy of NNC109-0012 in Subjects With Active Rheumatoid Arthritis
This trial is conducted in Europe. The aim of this trial is to evaluate the change in disease activity following 12 weekly s.c. (under the skin) doses of NNC109-0012 compared to placebo in subjects with active Rheumatoid…
- Trial name
- NCT01282255
- Testing
- NNC109-0012
- Where
- 29 sites in Czechia, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Novo Nordisk A/S
Rheumatoid Arthritis (RA)
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the…
- Trial name
- NCT03086343
- Testing
- Abatacept, Upadacitinib
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 657 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to…
- Trial name
- NCT05133297
- Testing
- TLL-018, Tofacitinib
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Rheumatoid Arthritis
Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease
The purpose of this study was to determine how effective and safe the study drug Olokizumab was in patients with Rheumatoid Arthritis (RA) who had been already receiving, but not fully responding to treatment with methotrexate…
- Trial name
- CREDO 1 (NCT02760368)
- Testing
- Olokizumab
- Where
- 40 sites in Belarus, Bulgaria and 1 more
- Volunteers
- 428 people
- Sponsor
- R-Pharm International, LLC
Rheumatoid Arthritis, Psoriatic Arthritis
Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis
The primary objective of this study is to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-Radiographical Axial Spondyloarthritis
- Trial name
- MANTA-RAy (NCT03926195)
- Testing
- Filgotinib, Standard of Care
- Where
- 71 sites in Bulgaria, Czechia and 6 more
- Volunteers
- 109 people
- Sponsor
- Lakefront Biotherapeutics NV
Arthritis, Rheumatoid
A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis
To evaluate the efficacy of fontolizumab in subjects with active rheumatoid arthritis as determined by a 50% improvement of an American College of Rheumatology criteria (ACR50) response at Week 14 (Stage A of study).
- Trial name
- NCT00281294
- Testing
- Fontolizumab
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- PDL BioPharma, Inc.
Rheumatoid Arthritis
An Exploratory Study of Changes in Synovial Immune Responses Following BMS-188667 Therapy in Subjects With Active Rheumatoid Arthritis on Background DMARDs Who Have Failed Anti-TNF Therapy
Study to assess changes in synovial tissue before and after treatment with Abatacept in subjects with RA who remained on their background disease modifying anti-arthritis medications but who have failed previous therapy with…
- Trial name
- NCT00162201
- Testing
- Abatacept
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs
This observational study will evaluate in clinical practice the change in Disease Activity Score (DAS28) in patients with rheumatoid arthritis and an inadequate response to DMARDs who are initiated on treatment with…
- Trial name
- NCT01388309
- Where
- 4 sites in Slovakia
- Volunteers
- 64 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
The primary objective of this study was to evaluate the long-term safety and tolerability of olokizumab (OKZ) 64 mg administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w) in subjects with moderately…
- Trial name
- CREDO 4 (NCT03120949)
- Testing
- Olokizumab 64 mg SC q4w, Olokizumab 64 mg SC q2w, Concomitant treatment
- Where
- 239 sites in United States, Argentina and 16 more
- Volunteers
- 2,106 people
- Sponsor
- R-Pharm International, LLC